Matthew Padley, from Hyde, Greater Manchester, was diagnosed with myeloma in 2023 after experiencing severe back pain which ...

Here is our Top Docs 2025 profile on Jeffrey Zonder, M.D., who is part of the Karmanos Cancer Institute’s Multiple Myeloma and Amyloidosis Multidisciplinary Team.

Last year, state epidemiologists studied an industrialized region east of Houston. They reported finding high rates of cancer ...

Collaboration between community practices and academic institutions is crucial for administering bispecific antibodies, with ...

Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

"This is what I had to do. My mother gave me my grandmother's silver, and I cashed it in to pay for my medical bills," ...

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

As September concludes, the landscape of hematologic oncology continues to evolve, spanning the full spectrum of blood cancer ...

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...